Citigroup initiated coverage on Cytokinetics with a new price target
$CYTK
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $86.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $87.00 | Overweight | Barclays |
| 12/18/2025 | $95.00 | Neutral → Buy | Goldman |
| 7/30/2025 | Mkt Perform | Raymond James | |
| 4/24/2025 | $55.00 | Overweight | Barclays |
| 2/7/2025 | $86.00 | Buy | Citigroup |
| 1/22/2025 | $80.00 | Buy | Stifel |
| 11/8/2024 | $80.00 | Outperform | RBC Capital Mkts |
| 8/13/2024 | $85.00 → $60.00 | Buy → Neutral | Goldman |
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outfl
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'
8-K - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
8-K - CYTOKINETICS INC (0001061983) (Filer)
Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00
Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00
Raymond James resumed coverage of Cytokinetics with a rating of Mkt Perform
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
4 - CYTOKINETICS INC (0001061983) (Issuer)
"On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the fourth quarter and full year of 2025. The company also provided full year 2026 financial guidance. "The fourth qu
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q4 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics'
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever
SC 13G - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)
SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)